Alzamend Neuro
Quarterly Financials
| Values in thousands | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -27 | -27 | -27 | -27 |
EBITDA | -2,953 | -2,169 | -970 | -2,672 |
EBIT | -2,870 | -2,197 | -998 | -2,700 |
Net Income | -2,869 | -2,198 | -1,000 | -2,702 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -2,797 | -1,736 | -1,171 | -2,362 |
Cash | 710 | 2,713 | 4,449 | 5,620 |
Basic Shares | 3,337 | 3,804 | 3,380 | 2,106 |
Annual Financials
| Values in thousands | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -50 | -50 | -23 | |
EBITDA | -8,655 | -4,446 | -9,886 | -14,847 |
EBIT | -8,765 | -4,496 | -9,937 | -14,870 |
Net Income | -8,772 | -4,514 | -9,947 | -14,878 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -8,922 | |||
Free Cash Flow | -8,067 | -6,868 | -8,417 | -8,923 |
Cash | 710 | 3,948 | 376 | 5,140 |
Basic Shares | 3,337 | 450 | 75 | 72 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-04-30 | -$0.74 |
2026-01-31 | -$0.58 |
2025-10-31 | -$0.30 |
2025-07-31 | -$1.28 |